The technology based on cell or tissue cultures is very useful for the production of bioactive compounds. These molecules, depending on the class they belong to, can be used in the food, pharmaceutical and cosmetic industry. In particular, the developed technology is addressed to the optimization of bioactive compounds in plant cell/tissue cultures having the biosynthetic pathway of the compound of interest.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 5 of 5
The object of the technology is the development of a transferable methodology from the laboratory scale to the pilot scale to be validated in the industrial setting for the treatment of basic waste of natural polymers of agro-food or manufacturing industry.
Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:
Recently, it has been demonstrated that Raman spectroscopy can play a fundamental role in assisting the work of the anatomopathologist by allowing classification of oncological samples with practically 100% accuracy in oncological diagnosis.
Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.